Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by capebretongirlon Apr 29, 2021 11:17am
266 Views
Post# 33090980

DISAPPOINTING

DISAPPOINTINGThe recent sp performance here has disappointed everyone - I doubt that even the most steadfast of longs would claim they are happy at .65 - hopefully however, with the catalysts coming up to and including May 17, we see a turn around and begin a new valuation range.

Whats unacceptable is the brain numbing experience we have to endear here - read: having to sort through the daily idiotic posts of the half wits.  Why anyone with accounts created today would think they might be given even a shred of credibility is beyond me.  I have most of them on ignore but new ones keep rising from the dirt pile where these vermin live. I suggest we just hit that ignore feature and ultimately leave them talking to themselves as they really arent worth the effort of opening their blogs.
<< Previous
Bullboard Posts
Next >>